10 Deaths in One Week: Ebola Surge in Congo Camp Pressures Vaccine & Diagnostic Pipeline

For biotech and pharma firms, the unfolding crisis in Bunia, DRC is a stark reminder of the gap between innovative countermeasures and real-world delivery. While Merck’s Ervebo vaccine and newer candidates exist, this outbreak’s rapid pace and community resistance to testing expose vulnerabilities in last-mile distribution and diagnostic acceptance.

At least 30 people have died with Ebola-like symptoms since early May in Kigonze camp, a sprawling settlement of over 15,000 displaced civilians in Bunia, northeastern Democratic Republic of Congo. The death rate is unprecedented—camp officials say the site normally records one to three fatalities per month, but 10 were buried in just one week in mid-June. Most worrying, families and patients had, until Thursday June 18, refused to allow testing of either the living or the dead, making it impossible to confirm whether Ebola is the cause. All victims exhibited headaches, fever, and vomiting, which are hallmark signs of the viral hemorrhagic fever. The outbreak was officially declared by Congolese health authorities on May 15, yet the World Health Organization said on June 19 that 75 health workers have already been infected and 17 have died, indicating the virus was likely circulating for months before it was recognized.

“

At least 30 people have died with Ebola-like symptoms since early May in Kigonze camp, a sprawling settlement of over 15,000 displaced civilians in Bunia, northeastern Democratic Republic of Congo.

The implications are severe. Ebola spreads through direct contact with bodily fluids, and its presence in a crowded, unsanitary camp for internally displaced people—where more than 5 million people live in eastern Congo—could ignite a much larger epidemic. The refusal of testing not only delays clinical confirmation and isolation but also hampers safe burial practices that are critical for cutting transmission chains. Footage from June 18 showed health workers in hazmat suits disinfecting bodies and preparing small coffins, while mourners wailed next to a crucifix. This resistance, rooted in fear, mistrust, and possibly misinformation, echoes the community pushback that marred the devastating 2014–2016 West African outbreak. Back then, safe burial practices and enhanced diagnostics proved pivotal; here, the inability to test means the actual case count may be far higher.

The outbreak also shines a harsh light on the disconnect between biomedical progress and field reality. While an effective Ebola vaccine (Merck's Ervebo) exists and was used in ring vaccination campaigns during the 2018–2020 DRC outbreaks, it is not clear whether vaccination has reached this camp. Newer one-dose candidates from Johnson & Johnson and others sit in stockpiles. Yet supply is one thing; acceptance is another. The camp's resistance to testing suggests a population that is not merely uninformed but actively distrustful of outside medical teams. Overcoming this will require culturally sensitive community engagement, mobile diagnostics (such as rapid antigen tests), and a massive scale-up of vaccination—resources that are often scarce in the DRC's protracted humanitarian crisis.